HomeLatest Pharma-NewsAZ's NDA filing anticipated based on positive data from interim analysis Latest Pharma-News AZ’s NDA filing anticipated based on positive data from interim analysis By admin June 22, 2022 0 50 Share FacebookTwitterWhatsAppLinkedin Share FacebookTwitterWhatsAppLinkedin Previous articleFDA Announces Plans for Proposed Rule to Reduce Addictiveness of Tobacco ProductsNext articleNovartis Tabrecta receives EC approval for METex14 skipping advanced nSCLC RELATED ARTICLES Latest Pharma-News Novartis Pluvictoâ„¢ demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic hormone-sensitive prostate cancer admin - June 4, 2025 Latest Pharma-News FDA Launches Agency-Wide AI Tool to Optimize Performance for the American People admin - June 4, 2025 Latest Pharma-News J&J announced Icotrokinra results show 75% of adolescents with plaque psoriasis achieved completely clear skin admin - April 11, 2025 LEAVE A REPLY Cancel reply Comment: Please enter your comment! Name:* Please enter your name here Email:* You have entered an incorrect email address! Please enter your email address here Website: Save my name, email, and website in this browser for the next time I comment. Δ - Advertisment - Most Popular Novartis Pluvictoâ„¢ demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic hormone-sensitive prostate cancer June 4, 2025 FDA Launches Agency-Wide AI Tool to Optimize Performance for the American People June 4, 2025 J&J announced Icotrokinra results show 75% of adolescents with plaque psoriasis achieved completely clear skin April 11, 2025 Sanofi’s Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosis April 9, 2025 Load more